Latest Us Market News

Scales Corporation delivered a record first half in 2026 with revenues soaring 105% to NZ$762.1 million and underlying EBITDA up 18% to NZ$102.2 million. The diversified agribusiness raised its full year profit guidance despite challenges in Europe and the Middle East.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.

OD6 Metals has recalibrated its Horseshoe fluorspar grades upward by nearly 13% following a re-assay program, confirming exceptional high-grade mineralisation near surface at its Quinn Project in Nevada.

Mader Group Limited has surpassed $1 billion in revenue for the first time, reporting a 15% increase in both revenue and net profit after tax for the financial year ended 30 June 2026. The company continues to expand its global footprint with strong growth in Australia and North America.

Andromeda Metals has successfully produced 4N High Purity Alumina (HPA) with 99.9986% purity at continuous pilot scale, marking a crucial step towards commercialisation and customer evaluation under a strategic supply agreement with Traxys.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.

Reece Limited posted a 4.5% revenue increase to $9.38 billion in FY26, driven by a strong ANZ recovery and tempered by ongoing challenges in the US residential market. Despite flat EBITDA and a slight dip in net profit, the company unveiled a revamped long-term executive remuneration plan aligned with its 2030 strategy.

Ovanti Limited has launched a 1-for-1 entitlement offer to raise approximately AUD 2.293 million at 0.2 cents per share, targeting working capital and offer costs. The offer closes on 1 September 2026 and includes a top-up facility for additional shares.

Guzman y Gomez (ASX: GYG) reported strong FY26 growth with network sales rising 18% and underlying NPAT up 30%, while completing its exit from the US market and announcing a 48 cents fully franked dividend.

Ovanti Limited has announced a complete global exit from the Buy Now Pay Later sector, ceasing all BNPL activities and shifting its focus to its established iSentric business in Southeast Asia, alongside significant cost reductions and imminent legal action against its former US BNPL CEO.